Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
Objective: To determine the distribution and density of metabotropic glutamate 2 (mGlu2) receptors in the motor loop of the basal ganglia in 6-hydroxydopamine (6-OHDA)-lesioned rats…Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?
Objective: To determine whether levodopa treatment starting at a very young age can prevent the development of the full clinical phenotype in Lesch-Nyhan disease. Background:…Effect of differences in stomach and small intestine pH on response to levodopa in patients with Parkinson’s Disease.
Objective: To examine levels of stomach and small intestine (SI) pH in relation to variable clinical responses to doses of levodopa in Parkinson’s disease (PD)…Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease
Objective: To evaluate the effect of levodopa on the blood activity of calpains in patients with PD Background: Parkinson's disease (PD) is a chronic progressive…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT
Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 57
- Next Page »